This is the focus of Dartmouth Medical Research — a Canadian start-up based in Halifax, Nova Scotia, who has a bone adhesive technology and is focused on developing and launching the product into market. The “glue” would provide a simple and fast method of fixing fractures, especially ones where there may be many small fragments that are difficult to fix by conventional means. The adhesive holds bones together while providing more comfort to patients and increasing recovery time.
Working under the direction of University of Alberta Professor Stephanie Yanow and PhD student Catherine Mitran, Ina is looking at samples from pregnant women in several regions in South America who have been infected with a type of malaria parasite called Plasmodium vivax. She’s then exploring the cross-reaction of those samples to that of pregnant women who’ve been infected by a different malaria parasite, Plasmodium falciparum, to see if the first species can create antibodies that contribute to protection against the second species.
This summer, Alexia’s working on a research project with Dr. Anne Ellis at Queen’s University’s Department of Biomedical and Molecular Sciences. Dr. Ellis’s research explores allergies and their impact on the Canadian population. Alexia’s project will help determine whether links exist between local pollen counts, a mother’s allergies (or lack of them), and biomarkers of children’s potential allergies in umbilical cord blood. From there, researchers will better understand the impact of pollen on children’s health outcomes and whether pollen-related allergies can be prevented.
Supervised by Assistant Professor Eftekhar Eftekharpour, Jesua is part of a research team that is investigating a possible biological connection between diabetes and dementia. While recent population studies point to a correlation between diabetes and an increased risk of developing dementia, researchers don’t yet know the exact biological mechanisms that explain it. Jesua is spending his summer investigating one possible answer.
With the help of his Dalhousie Accelerate supervisors, Professor David Roach from the Rowe School of Business, and Professor Jan Haelssig from the Faculty of Engineering, Hamed has started a company to develop technology that will make continuous positive airway pressure (CPAP) therapy more comfortable for patients.
Although those figures sound alarming, researchers at the University of British Columbia (UBC) are one step closer to understanding — and treating —pediatric diseases such as colitis, Crohn’s disease, and others under the IBD umbrella.
Under the supervision of Dr. Laura Sly of UBC’s Department of Pediatrics, Eyler Ngoh, a PhD student, wanted to build on his previous research on the impact of an enzyme called SHIP. His initial work indicated that patients with low levels of SHIP experienced increased inflammation, a symptom common in IBD.
Professor Lorna Butler and her team at the University of Saskatchewan’s College of Nursing and the International Centre for Northern Governance and Development aim to address this issue through a research partnership with the International Mineral Innovation Institute (IMII) and Mitacs’ Accelerate program.
From there, new protocols for screening and handling blood products were enacted to prevent the spread of these diseases through blood donation programs.
Over 30 years later, infectious diseases such as Zika and West Nile virus pose new challenges for the safety of blood donation around the world; however, a partnership between a multidisciplinary team of researchers at Université Laval, Quebec-based Phytronix, and international biotechnology firm Waters Corporation could revolutionize screening technology for donated blood products.